Phillip L Palmbos
Associate Professor of Internal Medicine
NCRC Bldg 520, Room 1345
1600 Huron Parkway
Ann Arbor, MI 48109-2800
[email protected]

Available to mentor
Phillip L Palmbos
Associate Professor
  • Center Memberships
  • Recent Publications
    • Center Memberships
    • Center Member
      Rogel Cancer Center
    Recent Publications See All Publications
    • Journal Article
      Identification and characterization of prognostic isoforms associated with bladder cancer outcomes.
      Patsalis C, Bankhead A, Palmbos PL. Journal of Clinical Oncology, 2024 Feb 1; 42 (4_suppl): 683 - 683. DOI:10.1200/jco.2024.42.4_suppl.683
    • Journal Article
      TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes.
      Loriot Y, Petrylak DP, Rezazadeh Kalebasty A, Fléchon A, Jain RK, Gupta S, Bupathi M, Beuzeboc P, Palmbos P, Balar AV, Kyriakopoulos CE, Pouessel D, Sternberg CN, Tonelli J, Sierecki M, Zhou H, Grivas P, Barthélémy P, Tagawa ST. Ann Oncol, 2024 Apr; 35 (4): 392 - 401. DOI:10.1016/j.annonc.2024.01.002
      PMID: 38244927
    • Preprint
      TRIM29 promotes bladder cancer invasion by regulating the intermediate filament network and focal adhesion.
      Palmbos P, Wang Y, Jerome N, Kelleher A, Henderson M, Day M, Coulombe P. 2023 Dec 12; DOI:10.21203/rs.3.rs-3697712/v1
      PMID: 38168254
    • Journal Article
      Efficacy of sacituzumab govitecan (SG) in locally advanced (LA) or metastatic urothelial cancer (mUC) by trophoblast cell surface antigen 2 (Trop-2) expression.
      Loriot Y, Balar AV, Petrylak DP, Rezazadeh A, Grivas P, Flechon A, Jain RK, Agarwal N, Bupathi M, Barthelemy P, Beuzeboc P, Palmbos PL, Kyriakopoulos C, Pouessel D, Sternberg CN, Tonelli J, Elboudwarej E, Diehl L, Jürgensmeier JM, Tagawa ST. Journal of Clinical Oncology, 2023 Jun 1; 41 (16_suppl): 4579 - 4579. DOI:10.1200/jco.2023.41.16_suppl.4579
    • Journal Article
      Safety analysis by UGT1A1 status of TROPHY-U-01 cohort 1, a phase 2 study of sacituzumab govitecan (SG) in patients (pts) with metastatic urothelial cancer (mUC) who progressed after platinum (PT)-based chemotherapy and a checkpoint inhibitor (CPI).
      Loriot Y, Petrylak DP, Rezazadeh A, Flechon A, Jain RK, Gupta S, Bupathi M, Beuzeboc P, Palmbos PL, Kyriakopoulos C, Pouessel D, Sternberg CN, Tonelli J, Sierecki M, Zhou H, Grivas P, Barthelemy P, Balar AV, Tagawa ST. Journal of Clinical Oncology, 2023 Jun 1; 41 (16_suppl): 4514 - 4514. DOI:10.1200/jco.2023.41.16_suppl.4514
    • Proceeding / Abstract / Poster
      Abstract 1068: A precision CRISPR approach to target structural variant junctions in cancer
      Hulbatte RS, Yang H, Gratsch N, Kellher A, Palmbos PL, Ljungman M. Cancer Research, 2023 Apr 4; 83 (7_Supplement): 1068 - 1068. DOI:10.1158/1538-7445.am2023-1068
    • Journal Article
      A cohort study evaluating the clinical, environmental and genetic profiles of men with early-onset, aggressive prostate cancer.
      Fenton SE, Kocherginsky M, VanderWeele DJ, Morgans AK, Palmbos PL, Meeks JJ, Benning J, Kenny S, Martone BK, Szymaniak B, Hussain MHA. Journal of Clinical Oncology, 2023 Feb 20; 41 (6_suppl): 266 - 266. DOI:10.1200/jco.2023.41.6_suppl.266
    • Journal Article
      Primary analysis of TROPHY-U-01 cohort 2, a phase 2 study of sacituzumab govitecan (SG) in platinum (PT)-ineligible patients (pts) with metastatic urothelial cancer (mUC) that progressed after prior checkpoint inhibitor (CPI) therapy.
      Petrylak DP, Tagawa ST, Jain RK, Bupathi M, Balar AV, Rezazadeh A, George S, Palmbos PL, Nordquist LT, Davis NB, Ramamurthy C, Sternberg CN, Loriot Y, Agarwal N, Park CH, Tonelli J, Vance M, Zhou H, Grivas P. Journal of Clinical Oncology, 2023 Feb 20; 41 (6_suppl): 520 - 520. DOI:10.1200/jco.2023.41.6_suppl.520